Brian Strem
Chief Executive Officer bij KIORA PHARMACEUTICALS, INC.
Vermogen: 72 789 $ op 31-03-2024
Profiel
Brian Matthew Strem is the founder of Yellowbrick Bio LLC, where he holds the title of Executive Director & Managing Director since 2020.
Dr. Strem is also the founder of Okogen, Inc., Bayon Therapeutics, Inc...
Dr. Strem's current job is at Kiora Pharmaceuticals, Inc., where he started in 2021 and holds the titles of President, Chief Executive Officer & Director.
Dr. Strem has a doctorate degree from the University of California, Los Angeles and an undergraduate degree from Cornell University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 15-03-2024 | 103 100 ( 0.39% ) | 72 789 $ | 31-03-2024 |
Actieve functies van Brian Strem
| Bedrijven | Functie | Begin |
|---|---|---|
| KIORA PHARMACEUTICALS, INC. | Chief Executive Officer | 26-07-2021 |
Okogen, Inc.
 Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA. | Founder | - |
Yellowbrick Bio LLC
 Yellowbrick Bio LLC Pharmaceuticals: MajorHealth Technology Part of Kiora Pharmaceuticals, Inc., Yellowbrick Bio LLC is a private company that manufactures ophthalmological pharmaceutical products. The company is based in Solana Beach, CA. The company was founded in 2020 by Brian Matthew Strem. Yellowbrick Bio was acquired by Kiora Pharmaceuticals, Inc. on October 21, 2021 for $7.22 million. | Founder | 01-01-2020 |
| Bayon Therapeutics, Inc. | Founder | - |
Opleiding van Brian Strem
| University of California, Los Angeles | Doctorate Degree |
| Cornell University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| KIORA PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Okogen, Inc.
Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA. | Commercial Services |
Yellowbrick Bio LLC
Yellowbrick Bio LLC Pharmaceuticals: MajorHealth Technology Part of Kiora Pharmaceuticals, Inc., Yellowbrick Bio LLC is a private company that manufactures ophthalmological pharmaceutical products. The company is based in Solana Beach, CA. The company was founded in 2020 by Brian Matthew Strem. Yellowbrick Bio was acquired by Kiora Pharmaceuticals, Inc. on October 21, 2021 for $7.22 million. | Health Technology |
| Bayon Therapeutics, Inc. |
